101,964 research outputs found
Gaipa Francesco
No full textVoce nel Dizionario. Ricostruzione storica dell'attività editoriale di Gaipa Lorenzo di Palermo con particolare riguardo ai libri di testo per la scuola e libri educativi nonchè la determinazione dei principi pedagogici e dei modelli formativi interni a detta produzione nel corso del tempo
XXXI National Conference of the Italian Society of Cytometry (GIC) October 8–11, 2013, Lucca, Italy
No full textThis year, the Conference has been preceded by a half a day satellite event devoted to the establishment of the “Professional Certification GIC Register” which will be committed to test, train, certify, and monitor the professional levels of the “Italian Cytometrists” under the responsibility of GIC.As dfar as "Professional Qualification” is concerned, authors summarized the strategic importance in Italy (as everywhere in the world)
to apply a “formal-serious-system” to take care and guarantee the high Professional level of people (Beginners as well as Seniors) involved in the area of analytical cytometry especially those having clinical impacts. The “national governance” should have in mind the patients’ care and the scientific society will have a crucial role in these initiatives.
With regard to “The role of Flow Cytometry in the immunophenotyping of Acute Leukemia.” authors delivered extensive details of what the board of this Project did in the recent past and what the enrolled “Expert Committee” is doing in the evaluation of the selected literature, in order to define future steps of the activity, which is the real impact of Flow Cytometry in this very important and promising area of this technology application
Different mitogenic capabilities of small and large granulosa cells isolated from bovine follicles
No full textFemale rainbow trout (Oncorhynchus mykiss) produce a single batch of eggs each year; synchronous growth of oocytes, all of which are ovulated at the same time, occurs in the two ovaries. To examine the regulatory mechanisms controlling egg size and number, virgin female rainbow trout were subjected to unilateral ovariectomy (ULO) during early vitellogenesis, and oocyte recruitment and growth in the remaining ovary were monitored. The study also set out to determine whether the presence of a second population of smaller oocytes in the maturing pool (induced by ULO) affected the timing of ovulation and/or the size of the eggs ovulated. Two months after ULO, there was no difference in the gonadosomatic index between ULO fish and controls. Compensatory ovarian hypertrophy resulted from the recruitment of a second population of primary oocytes into the vitellogenic pool. This population of smaller maturing oocytes in the ULO fish displayed growth rates up to twice those of the population of larger oocytes in the same ovary and of oocytes in controls. The growth rate of the population of larger oocytes in the ULO fish was not altered by the recruitment of a second maturing population. One month after ULO, fish had a lower concentration of plasma estradiol-17beta; than did controls; subsequently the concentrations of plasma estradiol-17β in the ULO and control groups were similar. After ULO, plasma levels of vitellogenin in the ULO fish did not differ from those in the control group throughout the study. At or close to ovulation, the fecundity of ULO fish was 75-80% that of controls. In the control group, oocytes appeared to reach a certain critical size before they were ovulated, and fish with higher fecundity ovulated later than their less fecund counterparts. ULO did not affect the timing of ovulation, and ULO fish ovulated eggs with a considerably greater size-range than did controls
Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media.
No full textIntroduction:
Despite having a proven immunosuppressive potential in vitro, human mesenchymal stromal cells (MSCs) are reported to display variable efficacy in vivo and, in fact, their proven benefit in the clinical practice is still limited and controversial.
Methods:
The interplay between clinical grade MSCs and pre-activated donor lymphocytes or selected lymphocyte subsets was studied in vitro. The kinetics of MSC growth and viability was evaluated by adhesion-dependent changes of culture plate impedance and biochemically by a colorimetric assay. Activation of natural killer (NK) cells was assessed as well, using a flow cytometry assay.
Results:
A strong inhibition of MSC growth was rapidly induced by the addition of pre-activated lymphocytes but not of resting lymphocytes. Inhibition seems not to be attributable to a single cell population, as similar results can be obtained by depleting NK cells or by using either selected CD4+ or CD8+ lymphocytes. In addition, conditioned medium (CM) from activated lymphocytes was able to inhibit MSC growth in a dose-dependent manner. Furthermore, licensing with IFN-γ partially protected MSCs from pre-activated lymphocytes but not from their CM. These results suggest an inhibitory role of lymphocyte-activation-derived substances. However, the identification of a single molecule responsible for MSC inhibition remained elusive, even if preliminary experiments showed that ATP and, to a lesser extent, TNF-α might play a role.
Conclusions:
These results suggest that survival of MSCs can be affected by soluble mediators released by activated lymphocytes. Thus it can be hypothesized that MSC immunosuppressive action in vivo could be impaired by ongoing immune activation through the release of inflammatory mediators
STAT5 Phosphorylation Status by Flow Cytometry Is a Rapid and Reliable Tool for Diagnosis and Follow up of Juvenile Myelomonocytic Leukemia
No full textIntroduction. Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder of infancy and early childhood characterized by overproduction of myeloid cells (Aricò M et al., Blood, 1997) and selective hypersensitivity of the hematopoietic precursor cells to GM-CSF (Emanuel PD et al., Blood, 1991). Current diagnostic criteria are based on matched clinical presenting features and laboratory findings according to established international criteria (reviewed in Emanuel PD, Leukemia, 2008). Sometimes though, in the absence of some of these specific conditions, arriving to a conclusive diagnosis may be challenging. When a novel rapid phospho-specific flow cytometric assay (phospho-flow) is used, we and others have reported in vitro specific phosphorylated STAT5 (p-STAT5) signaling signature in JMML. (Gaipa G et al., Leukemia, 2008; Kotecha N et al., Cancer Cell, 2008). Aim and Methods. Here, in order to validate the p-STAT5 phospho-flow assay as a new integrated tool in the diagnostic work-up of JMML we analyzed mononuclear cells from 14 JMML patients at diagnosis, 39 control subjects and 6 patients diagnosed with suspected JMML which were subsequently not confirmed. Samples were stimulated with GM-CSF at 0, 0.01, 0.1, 1.0, and 10 ng/mL. p-STAT5-responsive cells were identified within the CD34+/CD33+ subset, and quantified by scaling the maximum % of p-STAT5+ cells at 100 and the % of unstimulated p-STAT5+ cells to 0 (Kotecha N et al.). JMMLs and controls were compared at each dose using Wilcoxon’s test in order to identify the best dose with lowest significative p-value after correction for multiplicity with a Bonferroni’s method. Discriminating p-STAT5 % value was identified as the mean between the lowest of the JMML p-STAT5 values and the highest of the control subjects. Results. We found that a threshold of 18.9 % of p-STAT5+ cells, after stimulation with 0.1 ng/mL GM-CSF (p <0.01) , was the best condition to discriminate JMMLs (n 8) from control subjects (n 27). This algorithm was then applied on an independent cohort of JMMLs (n 6), control subject (n 12) and patients with suspected diagnosis of JMML subsequently not confirmed (n 6) and reached concordant results with a sensitivity of 0.83 and a specificity of 1.0 was reached. Positive and negative predictive values were 1.0 and 0.94, respectively. We also applied p-STAT5 phospho-flow assay in bone marrow aspirates from 3 JMML patients during one-year post- transplantation follow-up. Two of these 3 patients showed p-STAT5 value below the diagnostic threshold at any of time point (mean 9.71% [range 4.3%-10.6%], and 4.26% [range 0.26%-13.6%]), chimerism analysis and morphology examinations confirmed the remission status. The third patients relapsed 3 months after transplantation with a p-STAT5 value of 21.5% which increased to 41.1% one month later together with clinical disease progression. Conclusions. Patients with JMML show p-STAT5 hyper-responsiveness, and this condition can be rapidly assayed by phospho-flow technology in routine diagnostic work-up with high sensitivity and specificity, under appropriated technical standardization. Although we tested a very limited series of patients, our results also show that p-STAT5 response may represent a surrogate marker of disease activity in post-transplantation follow-up of JMML patients with potential clinical impact
Acute promyelocytic leukemia with unusual morphological features, absence of the t(15,17) and rearranged PML/RAR alpha genes
No full textThe CD133(+) Cell as Advanced Medicinal Product for Myocardial and Limb Ischemia.
No full textIschemic diseases are the major cause of death and morbidity in Western countries. In the last decade, cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. A subpopulation of bone marrow-derived immature ECPs, expressing the highly conserved stem cell glycoprotein antigen prominin-1 or CD133 marker, was shown to possess pro-angiogenic and antiapoptotic effects on ischemic tissues. The mechanisms implicated in CD133(+) cells ability to contribute to neovascularization processes have been attributed to their ability to directly differentiate into newly forming vessels and to indirectly activate pro-angiogenic signaling by paracrine mechanisms. A large body of in vivo experimental evidences has demonstrated the potential of CD133(+) cells to reverse ischemia. Moreover, several clinical trials have reported promising beneficial effects after infusion of autologous CD133(+) into ischemic heart and limbs exploiting various delivery strategies. These trials have contributed to characterize the CD133(+) manufacturing process as an advanced cell product (AMP). The aim of this review is to summarize available experimental and clinical data on CD133(+) cells in the context of myocardial and peripheral ischemia, and to focus on the development of the CD133(+) cell as an anti-ischemic AMP
CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease
No full textExpression of CD99 is higher on immature than on mature T cells. We postulated that this marker could be used to assess minimal residual disease (MRD) in T-lineage acute lymphoblastic leukemia (T-ALL). In diagnostic bone marrow (BM) samples from 27 children with T-ALL, expression of CD99 on leukemic lymphoblasts by flow cytometry was in median 7.7 times higher than on normal T lymphocytes from within the same sample. In 85% of cases, leukemic MFI values were higher than the mean MFI+2 s.d. of normal populations. We applied CD99 to study MRD in 39 follow-up samples from 15 consecutive T-ALL patients, and compared the results with those obtained with the well-established MRD-marker terminal deoxynucleotidyl transferase (TdT). Either antibody was combined in four-color flow cytometry with CD7, surfaceCD3, and cytoplasmicCD3. We found that CD99 was a valid complement to TdT in quantifying T-ALL MRD. Given a considerable interpatient variability, CD99 could be favorably used in nine patients, and TdT in other five patients. Both approaches showed a similar very low nonspecific background throughout 12 weeks from diagnosis (in median 0.002% of nucleated BM cells in patients with non-T ALL). We conclude that CD99 is a highly informative tool for MRD detection in T-ALL, bearing the advantage of surface expression in contrast to TdT
Bibliographie Hilarion G. Petzold 1958 – 2009 mit Anhang als Einführung
No full textDieses Archiv enthält die Gesamtbibliographie der Werke des Autors nebst einiger Texte „Über H. G. Petzold“ im Schlussteil der Bibliographie sowie einen Anhang mit einer Einführung in die Architektur des Werkes in seinem wissenslogischen Aufbau als Ausarbeitung seines „Tree of Science Modells“ (2007).This archive contains the complete bibliography of the author and some texts about H. G. Petzold, moreover an epilogue with an introduction to the architecture of the works in its epistemological structure and composition and as an elaborations of Petzold’s „Tree of Science Modell (2007).https://www.fpi-publikation.de/polyloge/01-2009-petzold-h-g-gesamtbibliographie-h-g-petzold-1958-2009-updating-november2009/peerReviewedpublishedVersio
- …
